On February 27, 2024 Adaptimmune Therapeutics plc announced the appointment of Cintia Piccina as Chief Commercial Officer, effective as of March 18, 2024. Ms. Piccina, age 51, has held senior management roles in public companies in the life sciences sector. Most recently, she has served as Chief Commercial Officer at AlloVir (Nasdaq: ALVR) helping to build the company?s commercialization capabilities and team to support the launch of the company?s first allogeneic multi Viral Specific T-cell (VST) therapy, AlloVir?s anticipated first commercial product.

Prior to her time at Adaptimmune from January 2022 to March 2023, Ms. Piccina served as the SVP Commercial Oncology and US General Manager at 2seventy bio and as the SVP Commercial Oncology and US General Manager at bluebird bio (Nasdaq: BLUE) since April 2020. Before that, Ms. Piccina spent over 20 years at Novartis from 1997 to April 2020, first in Brazil and subsequently in the United States, where she held a series of roles including serving as Vice-President, Global Oncology Cell and Gene Strategy & Program Management Office. Ms. Piccina holds a Doctorate in Pharmacy and Biochemistry from the University of Sao Paulo, Brazil, and an MBA from the Escola Superior de Propaganda e Marketing, Sao Paulo, Brazil.